In Project ERIS, mutations in SF3B1 occurred in 2.6% (95% CI, 1.4 to 4.9) of patients with AML, with a median upfront variant allele frequency (VAF) of 46.1%, consistent with its known heterozygous presentation; additional aggregate analyses have confirmed SF3B1mut frequencies of 2–5% in AML [21]. Here, SF3B1 is linked to acute myeloid leukemia.